Citations

Clear

16280 citation(s) found for "Yu, David".

DDEL-01. Enhancing drug retention in H3 K27-altered diffuse midline glioma: Combining convection-enhanced delivery with systemic efflux inhibition
Anderson, Jacob B. , Ge, Jizhi, Zhang, Liang , Rechberger, Julian S. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v154-v154

10.1093/neuonc/noaf201.0606 Get It

Abstract Pontine H3 K27-altered diffuse midline gliomas (DMGs) are rare, fatal pediatric brain tumors resistant to systemic therapies due to the blood-brain barrier (BBB) and efflux transporters (ETs), which actively clear drugs from the brain. Convection-enhanced delivery (CED) bypasses the BBB by directly infusing therapeutics into the tumor, but maintaining adequate drug concentrations remains a challenge. This study explores strategies to enhance drug-tumor residence time and improve treatment efficacy. Using chemical modeling, FDA-approved drugs identified in prior high-throughput screening efforts were classified based on physiochemical properties impacting CED pharmacokinetics, including BBB penetration and ET substrate status. Drug behavior was validated in patient-derived in vitro and in vivo DMG models. The impact of systemic drug co-administration on drug retention and therapeutic efficacy was evaluated using multiple patient-derived orthotopic xenograft (PDOX) models. ET substrate drugs exhibited rapid elimination from the brain post-CED, limiting their therapeutic potential. However, systemic everolimus administration prolonged drug retention and potentiated the effects of efflux substrate drugs delivered via CED (e.g., topotecan, ponatinib). This combinatorial approach significantly enhanced anticancer effects in multiple PDOX models, demonstrating improved tumor control compared to monotherapy. Overall, these findings suggest that pharmacological inhibition of ETs via systemic everolimus administration can enhance drug retention in DMG when combined with CED. The observed synergistic effects highlight a promising strategy to overcome drug clearance limitations and improve treatment outcomes. Further clinical investigation is warranted to validate this approach in patients.
CTNI-55. EXPLORING THE RELATIONSHIP BETWEEN PATIENT BASELINE CHARACTERISTICS WITH RESPONSES TO MIRDAMETINIB IN THE RENEU TRIAL OF CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMA (PN)
Shuhaiber, Hans, Viskochil, David , Bielamowicz, Kevin , Nickerson, Molly, Lokku, Armend, Weintraub, Lauren , Hajjar, Fouad, Babovic‐Vuksanovic, Dusica , Gershon, Timothy R. , Hirbe, Angela C. , Sidhu, Alpa , Nickerson, Molly, Weber, Michael

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v139-v139

10.1093/neuonc/noaf201.0551 Get It

Abstract BACKGROUND Mirdametinib, a MEK1/2 inhibitor, is the first FDA-approved medicine for both adults and children (≥2y) with NF1-PN not amenable to complete resection. In the phase 2b ReNeu trial (NCT03962543), confirmed objective response rate (ORR) was 41% in adults and 52% in children. This analysis explored relationships between baseline characteristics and mirdametinib responses in ReNeu. METHODS Confirmed ORR was the proportion of patients with ≥20% reduction from baseline in target PN volume by magnetic resonance imaging on consecutive scans during the 24-cycle treatment phase (“responders”) as assessed by blinded independent central review. Characteristics included age, body surface area (BSA), sex, race, ethnicity, target PN location, PN type (typical, nodular, or solitary nodular), target PN volume, and progression status. Rates of dose reductions and treatment-related adverse events (TRAEs) were evaluated. These factors were descriptively analyzed for potential relationships with confirmed objective response (data cutoff: 20September2023). RESULTS With mirdametinib, there was no clear difference between responders (n=53) and non-responders (n=61) in age (mean, 22.89 and 22.67y), BSA (mean, 1.42 and 1.51 m2), sex (60.4% and 57.4% female), race (83.0% and 68.9% White), or ethnicity (83.0% and 85.2% non-Hispanic/Latino). The majority of responders and non-responders had head/neck for target PN location (50.9% and 47.5%), typical PN type (81.1% and 63.9%), and baseline progression status (60.4% and 55.7%). Mean (95% CI) target PN volume was 283.43 (155.19, 411.66) and 415.74 (211.71, 619.77) mL, respectively. Dose reduction (11.3%; 18.0%) and TRAE rates (96.2%; 96.7%) were comparable. CONCLUSIONS This analysis suggests mirdametinib provides clinical benefit across a broad range of patient and NF1-PN tumor characteristics; a relationship between analyzed baseline characteristics and confirmed objective response was not established. Mean PN volume was higher in non-responders, though CIs overlapped. Dose reductions and emergence of TRAEs did not appear to impact response to mirdametinib. SUPPORT SpringWorks Therapeutics, Inc.
CTNI-06. UPDATE FROM THE LONG-TERM FOLLOW-UP (LTFU) PHASE OF RENEU: A PIVOTAL PHASE 2B TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED SYMPTOMATIC PLEXIFORM NEUROFIBROMA (PN)
Shuhaiber, Hans, Viskochil, David , Weintraub, Lauren , Langseth, Abraham, Lokku, Armend, Hajjar, Fouad, Antony, Reuben , Schiff, David , Nevel, Kathryn , Babovic‐Vuksanovic, Dusica , Hirbe, Angela C. , Moertel, Christopher L. , Sidhu, Alpa , Meade, Julia , Langseth, Abraham, Weber, Michael , Raslan, Ahmed M , Gershon, Timothy R.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v125-v125

10.1093/neuonc/noaf201.0503 Get It

Abstract BACKGROUND Mirdametinib is the first FDA-approved MEK1/2 inhibitor for both adults and children ≥2 years with NF1 who have symptomatic PN not amenable to complete resection. We report results from the phase 2b ReNeu trial (NCT03962543), including the LTFU. METHODS In ReNeu, mirdametinib was administered in 3-weeks-on/1-week-off 28-day cycles. Following the 24-cycle treatment phase, patients could continue mirdametinib in an optional LTFU. We report results through June 12, 2024, approximately 9 months from the previous data cutoff. RESULTS Fifty-eight adults and 56 children received mirdametinib. Median (range) duration of treatment was 21.8 (0.4, 54.4) months in adults and 25.4 (1.6, 48.5) months in children. Among LTFU-eligible patients, 26/31 (84%) adults and 32/37 (86%) children entered LTFU. Confirmed objective response rate (ORR, treatment+LTFU phases) was 47% (27/58; 95%CI, 33%, 60%) in adults and 55% (31/56; 95%CI, 42%, 69%) in children. Among confirmed responders, 18 adults and 19 children achieved a deep response (best target PN volume reduction from baseline of >50%). Median (range) best percentage change from baseline in target PN volume was –41% (–90%, 13%) in adults and –43% (–98%, 48%) in children. Median duration of response (DoR) was not reached for either age cohort. Treatment-related adverse events (TRAEs) in ≥25% of patients were dermatitis acneiform, diarrhea, nausea, and vomiting in adults; and diarrhea, dermatitis acneiform, and paronychia in children. Grade ≥3 TRAEs occurred in 17% of adults and 25% of children. Dose interruptions, dose reductions, and discontinuations due to TRAEs occurred in 9%, 17%, and 22%, respectively, of adults, and 14%, 14%, and 9%, respectively, of children. CONCLUSIONS Improved confirmed ORR was observed with longer duration of mirdametinib, with additional deep responses achieved in both adults and children. Mirdametinib continued to be well tolerated with a manageable safety profile and no new safety signals in the LTFU.
INNV-21. Initial experience with generative AI for clinical summarization in glioma MR interpretation
Black, David , Kaufmann, Tim , Charlotte, Rydberg, Kara, Schwartz, Ted, Passe, John, Port, Steven, Messina, Blezek, Daniel J. , Black, David, Carr, Carrie M. , Kaufmann, Tim, Kara, Schwartz, John, Port, Mark, Ian T. , Steven, Messina

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v229-v229

10.1093/neuonc/noaf201.0910 Get It

Abstract BACKGROUND Patients with primary brain tumors often have very complex histories, but an accurate understanding of their care timeline is critical to provide the best care possible. Extracting pertinent facts from the medical record can be time consuming and frustrating. We sought to apply generative AI large language models (LLM) to this problem in order to supply providers with concise, accurate, and focused data including graphs and tables. METHODS After evaluating multiple LLMs, GEMINI 2.5 Pro was selected. Prompt engineering was iteratively refined across a range of patients to generate concise outputs using tables, graphs, and prose to describe timing of chemoradiation, tumor markers, procedures, and trends in MRI results. The model inferred BT-RADS scores from the MRI report prose. Using a 5-point Likert scale, neuroradiologists assessed the AI-output both prospectively and retrospectively comparing it to the medical record. LLM’s compared AI summaries to source material. RESULTS Six neuroradiologists each ranked 25 prospective patient outputs as accurate (82%/16%/1%), useful (94%/6%/0%), trustworthy (86%/13%/1%), and satisfactory (86%/10%/1%) for Likert ratings of highly agree/agree/neutral, respectively. No responses were disagree or highly disagree. Interobserver agreement was high (Gwent AC2 > 0.95). The LLM evaluation of referenced portions of the record determined > 85% of summary statements were supported by source documents. While users estimated time savings of a 1-10 minutes per case, they felt the greater benefit was having more organized data presented efficiently. CONCLUSIONS AI summaries of the medical record of complex patients with primary brain tumors give providers an accurate, well-organized display of the pertinent facts necessary for high quality care and save time in chart review. These summaries, which are generated early each morning, have been found to be helpful and are now being incorporated into our clinical practice and multidisciplinary tumor board.
CTNI-74. PRIMARY RESULTS OF THE RANDOMIZED CLINICAL TRIAL OF BERUBICIN VS LOMUSTINE IN PATIENTS WITH GLIOBLASTOMA AFTER FAILURE OF PRIMARY THERAPY: DATA ANALYSIS AND FUTURE POSSIBILITIES
Kashraw, Mustafa, Dunbar, Erin, Aiken, Robert, Manrique, Teresa García, Muriel, C., Simonelli, Matteo , Salgado, María Ángeles Vaz , Muzyczenko, Zena, Picker, Don, Silberman, Sandra, Ducray, François , Hernández, Ainhoa , Muriel, Carolina, Piccioni, David Eric , Sepúlveda-Sánchez, Juan Manuel , Sherman, Wendy

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v144-v144

10.1093/neuonc/noaf201.0569 Get It

Abstract Berubicin is a unique anthracycline engineered to have the ability to cross the blood-brain barrier (BBB). Herein we present the primary results from a large global trial of Berubicin vs. Lomustine randomizing patients with progressive disease after only one prior therapy, all being IDH WT and stratified for MGMT methylation. The primary endpoint was overall survival (OS), secondary endpoints included progression-free survival (PFS), overall response rates (ORR) of complete (CR) and partial (PR) responses. Eligibility was determined radiologically by central reads based on progression of disease, and in 2.5 years 252 patients were enrolled with 168 randomized to Berubicin and 84 to Lomustine. Safety assessment showed that Berubicin was well tolerated and myelosuppressive side effects were manageable with growth factors. Importantly, although anthracyclines are known to cause cardiotoxicity, evaluation with frequent troponin measurements, ECG and ECHO testing revealed no evidence of impact on cardiac function. The primary endpoint, OS, showed Berubicin and Lomustine had similar outcomes. Median overall survival for Berubicin was 8.7 months (6.7, 9.9) and for Lomustine was 9.3 months (6.7, 10.7) with a Hazard Ratio of 1.13 (p = 0.5351). PFS of Berubicin and Lomustine were also similar (1.5 vs, 1.6 months). There were no responses in the Lomustine arm and stable disease in 35.2% of patients while Berubicin had a response rate of 5.8% (PR) and stable disease of 33.6% with a combined disease control rate (DCR) of 39.4%. Additional data will be presented and discussed. Anthracyclines are characteristically used in combination for systemic therapy (e.g. leukemia, lymphoma, certain breast cancers), so there is promise that combination therapy will be the next pertinent approach to treatment of GBM. Evaluation of activity against a range of pediatric brain tumors is being pursued and preliminary results will be presented at the time of the conference.
CTNI-07. UNDERSTANDING COMMONLY REPORTED (≥15%) TREATMENT-RELATED ADVERSE EVENTS IN THE RENEU TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMA (PN)
Ambady, Prakash , Maraka, Stefania , Sadighi, Zsila , Schiff, David , Nickerson, Molly, Lokku, Armend, Walbert, Tobias , Antony, Reuben , Nevel, Kathryn , Babovic‐Vuksanovic, Dusica , Nghiemphu, Phioanh L. , Klesse, Laura J. , Moertel, Christopher L. , Nickerson, Molly, Weber, Michael , Stapleton, Stacie L. , Meade, Julia , Gershon, Timothy R.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v125-v126

10.1093/neuonc/noaf201.0504 Get It

Abstract BACKGROUND Mirdametinib is the first FDA-approved MEK1/2 inhibitor for both adults and children (≥2y) with symptomatic NF1-PN. In ReNeu, symptomatic improvement and PN volume reductions were observed at the earliest assessments (~91 and ~152 days, respectively) and were sustained. This analysis evaluated time to first onset and resolution of commonly reported TRAEs in the ReNeu trial. METHODS Data cutoff (DCO) was September 20, 2023. Median time to first onset and resolution (days) for common TRAEs (≥15%) were evaluated for prepubescents (≥2 to <12y, n=32), postpubescents (≥12 to <18y, n=24), younger adults (≥18 to ≤50y, n=48), and older adults (>50y, n=10). RESULTS Common TRAEs were mostly grades 1 to 2 (83%). In prepubescents, median day (range) of onset was 32 (14, 263) for vomiting, 71 (19, 386) for dermatitis acneiform, 123 (1, 663) for diarrhea, 124 (52, 775) for paronychia, and 127 (2, 663) for nausea. For postpubescents, median day (range) of onset was 8 (1, 438) for diarrhea, 8 (2, 574) for nausea, 12 (1, 252) for dermatitis acneiform, 28 (2, 354) for vomiting, and 110 (43, 245) for paronychia. In younger adults, median day (range) of onset was 5 (1, 352) for nausea, 8 (2, 15) for dermatitis acneiform, 9 (2, 73) for diarrhea, and 29 (1, 264) for vomiting. For older adults, median day (range) of onset was 4 (1, 286) for diarrhea, 9 (2, 15) for nausea, and 13 (2, 38) for dermatitis acneiform. Time to resolution was variable between TRAEs and among patients in all age groups; 90% resolved completely by DCO. Among all patients, 18 had a TRAE of asymptomatic ejection fraction decrease, with all but one resolving by DCO. CONCLUSIONS Overall, common TRAEs arose before treatment benefits and were generally resoluble by DCO. Proactively managing TRAEs may improve treatment experience and adherence.
CTNI-41. RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF THE RADIOPHARMACEUTICAL [177LU]LU-DOTA-TATE IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA
Kurz, Sylvia C. , Zan, Elçin , Lobbous, Mina , Malkin, Mark G. , Miller, Alexandra , Torres-Trejo, Alejandro, Stevens, Glen , Zagzag, David , Golfinos, John G. , Shepherd, Timothy M. , Friedman, Kent, Cordova, Christine , Barbaro, Marissa , Dhawan, Andrew , Silverman, Joshua S. , Snuderl, Matija , Kondziolka, Douglas , Troxel, Andrea B. , Sulman, Erik P.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v135-v135

10.1093/neuonc/noaf201.0537 Get It

Abstract BACKGROUND Most meningiomas are considered benign tumors, however, a subset of meningiomas are characterized by a more aggressive clinical course and require multimodal treatment. Beyond surgery and radiation, there are no effective medical treatments available. Somatostatin receptor 2 (SSTR2) is expressed by the majority of meningiomas. [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) is a SSTR2-targeting radioligand therapeutic agent that has been successful in other oncological entities, including neuroendocrine tumors. Here we report the results of a phase 2 clinical trial (NCT03971461) evaluating 177Lu-Dotatate in patients with advanced and treatment-refractory intracranial meningiomas. METHODS In this multicenter, open-label, phase 2 study, adults with advanced intracranial meningiomas received 177Lu-Dotatate at 7.4 GBq (200 mCi) every eight weeks for four doses. [68Ga]Ga-DOTA-TATE (68Ga-Dotatate) PET was performed before and at the end of treatment. The primary endpoint was progression-free survival at 6 months (PFS-6). Correlative studies evaluated the association of PFS-6, objective response rate, progression-free survival, overall survival with radiographic tumor measurements, and 68Ga-Dotatate uptake on PET. RESULTS Thirty-two patients (F=21, M=11) with progressive meningiomas (WHO 1=7, WHO 2=24, WHO 3=1) were enrolled. Median age was 65.5 (range 41-78) years. All patients previously underwent tumor resection and at least one course of radiation. Three patients (9%) had received medical therapy. Treatment with 177Lu-Dotatate was well tolerated, no treatment-limiting toxicities were observed. Of 29 evaluable patients at the data cutoff, 19 patients (66%) had achieved PFS-6 (WHO 1=4, WHO 2=15). Radiographically, the best response was partial response (PR) in 2 patients (6%) and stable disease (SD) in 20 patients (63%). CONCLUSIONS Treatment with SSTR2-targeting 177Lu-Dotatate is well tolerated and 66% of patients achieved PFS-6, comparing favorably to historical benchmarks, 177Lu-Dotatate therefore may be a useful new therapeutic modality for patients with advanced meningiomas and will be further explored in MOMENTUM-1 (NCT#06955169), an open-label, randomized, phase 2 trial.
STEM-19. OLIG2 AND STAT5 TRANSCRIPTIONAL AXIS DRIVES GLIOMA STEM CELL PROLIFERATION AND INVASION
McNamara, James, Miller, Aunay , Orndorff, Keely, Nascari, David , Blomquist, Mylan, Flick, Matthew J. , Sereduk, Christopher, Loftus, Joseph C. , Hu, Leland , Tran, Nhan L. , Mehta, Shwetal , Tran, Nhan L , Orndorff, Keely, Flick, Matthew, Sereduk, Chris

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v81-v82

10.1093/neuonc/noaf201.0327 Get It

Abstract Glioma stem cells (GSCs) are key drivers of glioblastoma (GBM) progression, therapy resistance, and recurrence, making them critical therapeutic targets. While the lineage-defining transcription factor OLIG2 is critical for GSC maintenance, the molecular co-regulators and downstream pathways it engages remain poorly defined. Here, we identify a previously unrecognized, functionally significant interaction between OLIG2 and STAT5B, uncovering a novel regulatory axis in GSCs. Using proximity ligation assay (PLA), we demonstrate that OLIG2 interacts with STAT5 in human and mouse GSC models, particularly in EGFRvIII-mutant cells. We find that OLIG2 preferentially partners with STAT5B and not STAT5A. Knockdown studies in GSCs reveal that OLIG2 and STAT5B co-regulate critical oncogenes BIRC5 and NUSAP1, both of which are required for sphere formation and migration capacity of EGFRvIII positive GSCs. In orthotopic xenograft models, knockdown of either STAT5B or OLIG2 significantly prolongs survival reduces expression of stemness and invasion markers, SOX2, VIMENTIN, and NUSAP1. In contrast, STAT5A knockdown fails to recapitulate these phenotypes, underscoring the role of OLIG2-STAT5B signaling in GSCs. These findings reveal a novel OLIG2-STAT5B transcriptional circuit that plays a role in GSC stemness maintenance, invasion, and tumor growth, particularly in EGFRvIII-driven gliomas. Targeting this axis may offer a new avenue for GBM treatment.
CSIG-30. HISTONE H3.3 K27M AND G34R/V GLIOMA DRIVER MUTATIONS BLOCK H3.3 PHOSPHORYLATION AND TRAP CHK1 – LEADING TO ANEUPLOIDY
Langfald, Alyssa, Day, Charles , Daniels, David J. , Robinson, James, Hinchcliffe, Edward H.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v90-v90

10.1093/neuonc/noaf201.0364 Get It

Abstract Diffuse midline and diffuse hemispheric glioma contain the driver mutations H3.3 K27M and G34R/V, respectively. These mutations alter histone methylations, suggesting that dysregulation of gene expression may contribute to tumor formation. We recently reported that these mutations also inhibit the phosphorylation of H3.3 at Serine 31. Importantly, H3.3 S31A mice developed high-grade gliomas – similar to those from G34R and K27M mice – indicating that loss of phosphoS31 promotes gliomagenesis. Chk1, a key kinase in DNA damage response and mitotic fidelity, phosphorylates H3.3 S31. H3.3 S31 is phosphorylated at the pericentromere in metaphase and is typically absent during interphase. Reduction of S31 phosphorylation by H3.3 K27M, G34R, G34V, or S31A was sufficient to induce mitotic errors leading to aneuploidy. Using CRISPR/Cas9, we generated novel H3.3 WT/WT and WT/S31A lines from glioma patient-derived SF-8628 (H3.3 WT/K27M) and KNS-42 (H3.3 WT/G34V) cells. Immunofluorescence of metaphase spreads revealed H3.3 phosphoS31 at the pericentromeres as expected. Interestingly, total Chk1 and active Chk1 (pS296) were significantly enriched at the pericentromeres of H3.3 K27M and G34V cells, as compared to H3.3 WT cells. While total ATR and active ATR (pT1989) were present at the pericentromere, their levels were unaltered by the H3.3 mutations. Surface plasmon resonance of purified proteins revealed that Chk1 has two binding affinities for H3.3 - likely corresponding to the previously identified Chk1 phosphorylation sites (T11 and S31) on H3.3. Chk1 binding at one site was unaffected by H3.3 K27M, while the second site showed an altered dissociation from H3.3 K27M. In summary, our data suggest that the low pericentromeric pS31 levels associated with H3.3 glioma mutations result from Chk1 recognizing the mutant histone, but without completing a phosphorylation cycle, becoming trapped at the pericentromere. This result suggests that H3.3 mutations, by trapping Chk1, may impede Chk1 activities beyond just reducing H3.3 phosphorylation.
RADT-33. PROGNOSTIC AND PREDICTIVE EFFECT OF AGE IN MOLECULARLY-DEFINED LOWER GRADE GLIOMAS: A REPORT FROM THE PROSPECTIVE GLIOMA RESEARCH (PROGRES) DATABASE
Minniti, Giuseppe, Brown, Paul D. , Vogelbaum, Michael A., Mercurio, Ann, Siegelin, Markus D. , Touat, Mehdi, DeStephano, David, Shuryak, Igor , Roy, Soumyajit , Horowitz, David P. , Sisti, Michael B. , Bruce, Jeffrey N. , Canoll, Peter , Neugut, Alfred I. , Cheng, Simon K. , Kachnic, Lisa A. , Kinslow, Connor J , Kocakavuk, Emre , Tuohy, Kyle , Mansouri, Alireza , Touat, Mehdi , Ducray, François , Dehais, Caroline , Grinband, Jack , Yu, James , Walch, Henry , Parker, Mitchell I , Gallitto, Matthew , McKhann, Guy M. , Ostrom, Quinn T. , Pike, Luke R G , IWAMOTO, FABIO MASSAITI , Mehta, Minesh P. , Wang, Tony J. C.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v99-v100

10.1093/neuonc/noaf201.0403 Get It

Abstract PURPOSE Age over 40 years is commonly regarded as a “high risk” feature and potential indication for adjuvant chemoradiotherapy for patients with lower grade glioma in most clinical practice guidelines. However, these recommendations are based on retrospective observations and their subsequent incorporation into legacy clinical trials. It is unclear whether age remains a relevant prognostic factor in the molecular era. METHODS The Prospective Gliomas Research [PROGRES] Database contains individual patient-level data from 11 prospective clinical trials or observational registries, including seven international trials from the RTOG, EORTC, or Alliance cooperative groups. We determined the association of age with progression-free survival (PFS) in low grade or anaplastic glioma, stratified by isocitrate dehydrogenase (IDH1/2) status. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] Database). RESULTS We identified 1,619 and 1,271 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH-wildtype tumors were more common in patients >40 years (38% vs, 5%, odds ratio: 11.3 [95%CI 6.5 – 19.7]). Age was associated with PFS in IDH-wildtype (5-year PFS: 6% vs, 24%, P =.003) but not in IDH-mutant glioma (60% vs, 59%, P = 0.22, P value of interaction <.001). In IDH-wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% vs, 28%), EGFR amplification (41% vs, 15%), and chromosome +7/-10 alteration (57% vs, 25%). Age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone in IDH-mutant glioma. CONCLUSION Older age is a putative surrogate for IDH-wildtype status, but was not an independent predictor of progression in IDH-mutant lower grade glioma and did not predict benefit from chemoradiotherapy. In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.